Navigation Links
Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge
Date:6/26/2008

MONTVALE, N.J., June 26 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer Ingelheim's Mirapex(R) Tablets (pramipexole dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

In his ruling, District Court Judge Joseph J. Farnan, Jr. found that the patent claims at issue in the litigation were invalid on the grounds of nonstatutory double patenting.

Barr's Abbreviated New Drug Application (ANDA) for a generic Mirapex product received final approval from the U.S. Food and Drug Administration (FDA) in February 2008. Barr believes that it is the first company to file an ANDA with a paragraph IV certification for Mirapex Tablets, 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

"We are very pleased with the Court's favorable decision regarding the patent on Mirapex, and are currently reviewing the opinion in the case and evaluating our options," said Bruce L. Downey, Barr's Chairman and CEO.

Barr filed its ANDA for generic Mirapex Tablets, 0.25mg containing a paragraph IV certification with the FDA in May 2005 and in June 2005 amended its application to include the tablet strengths 0.125mg, 0.5mg, 1mg, and 1.5mg. Following receipt of the notice from the FDA of the application's acceptance for filing, Barr notified the New Drug Application (NDA) holder and patent owner. On September 26, 2005, Boehringer Ingelheim filed suit in the U.S. District Court in Delaware to prevent Barr from proceeding with the commercialization of its product, formally initiating the patent challenge process under t
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4

Related biology technology :

1. Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6
2. ValGenesis, Inc. Announces Worldwide Release of Validation Life Cycle Management System - ValGenesis 2.0
3. Wyeth Pharmaceuticals Announces Organizational Change
4. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
5. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
6. Cell Biosciences Announces New Leadership
7. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
8. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
9. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
10. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Boston Scientific Corporation (NYSE: ... public offering of $2 billion aggregate principal amount of ... The public offering consists of $850 million of ... 6.00 percent notes due January 2020 and $300 million ... Scientific plans to use the net proceeds for general ...
(Date:12/14/2009)... Dec. 14 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that, owing to ... fibrillation drug market will increase more than sevenfold ... in 2018 in the United States, France, Germany, ... The new Pharmacor report entitled Atrial Fibrillation ...
(Date:12/11/2009)... 11 EntreMed, Inc. (Nasdaq: ENMD ... in royalty revenue from sales of Thalomid® during ... of $3.3 million. In addition, the Company ... revenue for fiscal 2009. The difference in ... will be reflected in the fourth quarter financial ...
(Date:12/11/2009)... a new explanation for differences in the severity of mental ... gene, the more serious the handicap. The genetic defect is ... is the amount of copies of the GDI1 gene that ... American Journal of Human Genetics , and are the result ... VIB, a life sciences research institute in Flanders, Belgium at ...
Breaking Biology Technology:Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2
... Jan. 16 Roche (OTCQX:,RHHBY; SWX: ROG.VX; RO.S), a ... it has extended its,offer to acquire all of the ... VMSI ) to 5:00 p.m., New York City time ... scheduled to expire at 5:00,p.m., New York City time, ...
... NEW YORK, Jan. 16 Bristol-Myers Squibb,Company (NYSE: ... and full,year of 2007 on Thursday, January 31. During ... executives will review financial information and will,address inquiries from ... are invited to listen to a live,webcast of the ...
... Statement on 1/11/08, SPOKANE, Wash., Jan. 16 ... the use of estriol in compounded hormone,replacement therapy. While ... medical practice. Cheryle Hart, M.D.,is Mayo Clinic trained and ... by Hart in 1997. She is also the medical ...
Other Biology Technology:Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Roche Extends Tender Offer for Ventana 5Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol 2
(Date:12/15/2009)... December 2009 - Scientists at VIB and Ghent University ... the treatment of septic shock, the major cause of ... of nitric oxide (NO) gas in mice with septic ... the animal,s organs showed much less damage, while their ... expectations, since it is generally assumed that nitric oxide ...
(Date:12/15/2009)... consumers can look forward to ultra-low powered or ... and mobile phones. This is made possible with ... are critical elements for power optimisation and higher ... Analog IC design is the key enabling capability ... the nation in advanced analog and mixed signal ...
(Date:12/14/2009)... -- (Dec. 14, 2009) -- Researchers at Rice University ... single nanoparticle that can be tracked in real time ... tags them with a fluorescent dye and kills them ... first examples from a growing field called "theranostics" that ... diseases in a single procedure. , The research is ...
Breaking Biology News(10 mins):Septic shock: Nitric oxide beneficial after all 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Tracking new cancer-killing particles with MRI 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 12800 1Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 12800 2Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane 12800 3SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 1SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 2SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 3SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 4SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 5SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 6SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 7SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 8SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 9SIMPONI 28TM 29 28golimumab 29 Receives Positive Opinion From CHMP for Once Monthly Subcutaneous Treatment of Rheumatoid Arthritis Psoriatic Arthrit 4654 10Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 1Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 2Brown Takes Over Reins as Chair of AOSSM Medical Publishing Board of Trustees 50148 3
... that lead poisoning may have played a role in the ... been caused by the concentration of grape juice in lead ... to the environment, the annual production of lead continues to ... and electronic components. However, there has thus far been little ...
... the Arabidopsis plant flowers in response to changes in ... perceived seasonal changes in day length, which triggers a ... from the leaf to the shoot apex, where flowering ... signal remained unclear. , This new research, carried ...
... non-human primates infected with the influenza virus that killed 50 ... found a critical clue to how the virus killed so ... in the journal Nature, a team led by University of ... modern history's most savage influenza strain - unleashes an immune ...
Other Biology News:Lead with a poisonous electron shield 2Scientists unlock secret of what makes plants flower 2Study uncovers a lethal secret of 1918 influenza virus 2Study uncovers a lethal secret of 1918 influenza virus 3
...
... Bioluminescence assay for monitoring acetylcholinesterase (AChE) ... rapid (less than 5 min), non-radioactive and ... that uses the natural substrate, acetylcholine. A ... presence of active AChE into a change ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
McCoy's 5A Medium. Without Tryptose or Phosphate Broth. Contains Sodium Bicarbonate....
Biology Products: